Program
nomlabofusp
Also written as “CTI-1601” and “Nomlabofusp”.
Its studies are mostly in Friedreich Ataxia, led by Larimar Therapeutics.
Furthest: phase 3, since Aug 17, 20266 company-led studies, 2 open or runningNext primary completion: Jan 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Larimar Therapeutics | 62 open or running | phase 3since Aug 17, 2026 | Nov 14, 2019 | Jan 2027phase 2 · NCT06447025 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2019First study: phase 1 study in Friedreich AtaxiaFirst studyNCT04176991 · 28 enrolled · United States
- Aug 17, 2020Phase 1 study in Friedreich AtaxiaNCT04519567 · 27 enrolled · United States
- Oct 5, 2022Phase 2 study in Friedreich AtaxiaNCT05579691 · 28 enrolled · United States
- Feb 15, 2024Phase 2 study in Friedreich AtaxiaNCT06447025 · 85 planned · United States
- Nov 6, 2024Phase 1 study in Friedreich AtaxiaNCT06681766 · 18 enrolled · United States
- Aug 17, 2026Phase 3 study in Friedreich AtaxiaPhase 3 reachedNCT07778836 · 150 planned · United States
Ahead
- Jan 2027Primary completion: phase 2 study in Friedreich AtaxiaNCT06447025
- Jul 2029Primary completion: phase 3 study in Friedreich AtaxiaNCT07778836
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07778836Friedreich Ataxia · United States | 3 | Recruiting | Jul 2029 | 150 |
| NCT06681766Friedreich Ataxia · United States | 1 | Terminated | Apr 27, 2025 | 18 |
| NCT06447025Friedreich Ataxia · United States | 2 | Recruiting | Jan 2027 | 85 |
| NCT05579691Friedreich Ataxia · United States | 2 | Completed | Dec 4, 2023 | 28 |
| NCT04519567Friedreich Ataxia · United States | 1 | Completed | Mar 16, 2021 | 27 |
| NCT04176991Friedreich Ataxia · United States | 1 | Completed | Oct 31, 2020 | 28 |
How it is read
Names in the registry
- “CTI-1601”, 4 entries
- “Nomlabofusp”, 2 entries
Conditions, from the studies’ own filings
- Friedreich Ataxia, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.